06.08.2010 • News

Huntsman Posts Better-Than-Expected Q2 Profit

Chemicals maker Huntsman posted a higher-than-expected quarterly profit on Thursday as sales jumped across its units, pushing shares up 4.7% in premarket trading. For the period that ended June 30, the company posted net income of $114 million, or 47 cents per share, compared with $406 million, or $1.51 per share, in the year-ago period.

The year-ago results include a settlement with two banks over a botched sale of Huntsman to a private equity firm. Excluding one-time items, the company posted a profit of 31 cents per share.

Analysts expected earnings of 8 cents per share, according to Thomson Reuters I/B/E/S. Revenue rose 27% to $2.34 billion. Analysts expected revenue of $2.19 billion.

Huntsman, based in The Woodlands, Texas, said sales in its polyurethane business rose 34% and pricing increased 11%. Polyurethane is used to construct a wide range of products, including foam insulation and Spandex. Its shares rose 48 cents, or 4.7%, to $10.75 in premarket trading. The stock has traded between $6.10 and $14.25 in the past 52 weeks.

Company

Huntsman

Everslaan 45
3078 Everberg
Belgium

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read